FRST:NASDAQPrimis Financial Corp. Analysis
Data as of 2026-05-19 - not real-time
$13.95
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Primis Financial Corp. trades at a price well below its 20‑day and 50‑day simple moving averages, suggesting a short‑term technical weakness despite an overall bullish trend. The RSI hovering in the mid‑40s signals neither overbought nor oversold conditions, while the MACD histogram remains negative, hinting at lingering bearish momentum. Valuation metrics are compelling: a trailing P/E of roughly 7.5 versus an industry average near 16.7, a price‑to‑book below 1, and a dividend yield close to 3% with a modest payout ratio. However, operating cash flow is negative and revenue has contracted by more than 20%, raising questions about the sustainability of earnings. The stock’s beta below 1 and a volatility of over 23% point to moderate market sensitivity but heightened price swings. Analysts’ price targets cluster around $17, implying an upside of over 20% from the current level, while the Fear & Greed Index sits in “Extreme Greed,” reflecting strong market appetite for risk. The balance sheet shows substantial debt, yet the debt‑to‑equity ratio is reported as zero, indicating a strong equity base relative to liabilities. Decreasing trading volume adds a liquidity nuance, but the regional banking sector’s regulatory environment remains a steady backdrop. In sum, FRST appears undervalued with attractive yield, but faces short‑term technical headwinds and longer‑term cash‑flow challenges.
Given these dynamics, investors may consider a cautious stance: hold in the near term while monitoring volume and MACD signals, but position for a potential rebound as the market re‑prices the stock toward analyst targets. The dividend’s modest payout and the stock’s low valuation provide a margin of safety, yet the negative cash flow and revenue decline suggest that any upside will likely be incremental and contingent on improved earnings quality.
Given these dynamics, investors may consider a cautious stance: hold in the near term while monitoring volume and MACD signals, but position for a potential rebound as the market re‑prices the stock toward analyst targets. The dividend’s modest payout and the stock’s low valuation provide a margin of safety, yet the negative cash flow and revenue decline suggest that any upside will likely be incremental and contingent on improved earnings quality.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near recent support level
- Bearish MACD histogram despite bullish trend
- Decreasing trading volume indicating lower liquidity
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation discount to peers (low P/E, P/B)
- Attractive dividend yield with low payout ratio
- Upside potential of >20% based on analyst target prices
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustained undervaluation relative to industry fundamentals
- Stable dividend providing income over time
- Potential for earnings improvement if cash‑flow issues are resolved
Key Metrics & Analysis
Financial Health
Revenue Growth-22.70%
Profit Margin23.25%
P/E Ratio7.5
ROE11.49%
ROA1.16%
P/B Ratio0.8
Op. Cash Flow$-77988000
Industry P/E16.7
Technical Analysis
TrendBullish
RSI46.3
Support$13.74
Resistance$14.97
MA 20$14.32
MA 50$13.72
MA 200$12.36
MACDBearish
VolumeDecreasing
Fear & Greed Index89.61
Valuation
Target Price$17.08
Upside/Downside22.46%
GradeUndervalued
TypeValue
Dividend Yield2.86%
Risk Assessment
Beta0.83
Volatility23.37%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.